Zika virus disease

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:448237A92.5
Who is this for?
Show terms as
4FDA treatments3Active trials47Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Zika virus disease (also called Zika fever or simply Zika) is an infectious disease caused by the Zika virus, which is primarily spread through the bite of infected Aedes mosquitoes — the same type of mosquito that spreads dengue and chikungunya. The virus can also be transmitted from a pregnant mother to her unborn baby, through sexual contact, and through blood transfusions. Most people infected with Zika virus have mild symptoms or no symptoms at all. When symptoms do occur, they typically include fever, rash, joint pain, and red eyes (conjunctivitis), lasting several days to a week. While the illness itself is usually mild in adults, Zika gained worldwide attention because of its devastating effects during pregnancy. Infection during pregnancy can cause serious birth defects, most notably microcephaly (an abnormally small head) and other brain abnormalities in the developing baby, collectively known as congenital Zika syndrome. In rare cases, Zika infection in adults can trigger Guillain-Barré syndrome, a condition where the immune system attacks the nerves, causing muscle weakness and sometimes paralysis. There is currently no specific antiviral treatment or vaccine for Zika virus disease. Treatment focuses on relieving symptoms with rest, fluids, and pain relievers like acetaminophen. Prevention through mosquito control and bite avoidance remains the most important strategy.

Also known as:

Key symptoms:

Low-grade feverSkin rash, often itchy and spreading across the bodyJoint pain, especially in the hands and feetRed or pink eyes (conjunctivitis) without pusMuscle painHeadachePain behind the eyesFatigue and general tirednessSwollen jointsAbdominal painNausea or vomitingIn newborns: abnormally small head (microcephaly)In newborns: vision and hearing problemsIn rare cases: muscle weakness from Guillain-Barré syndrome

Clinical phenotype terms (34)— hover any for plain English
Maculopapular exanthemaHP:0040186Abnormal cerebrospinal fluid morphologyHP:0002921Increased circulating IgM levelHP:0003496Wrist swellingHP:0001225Ankle swellingHP:0001785Transient hearing impairmentHP:0012779Chorioretinal atrophyHP:0000533Lens subluxationHP:0001132
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Sep 2025MAPS PrEP Van Study

Duke University — PHASE4

TrialRECRUITING
Mar 2025RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

Henry M. Jackson Foundation for the Advancement of Military Medicine — PHASE1

TrialRECRUITING
Dec 2024Screen Smart: Using Digital Health to Improve HIV Screening and Prevention

Children's Hospital Medical Center, Cincinnati — NA

TrialRECRUITING
Nov 2024A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

National Institute of Allergy and Infectious Diseases (NIAID) — PHASE1

TrialACTIVE NOT RECRUITING
Nov 2024Assessing the Use of MY-RIDE, a Just-in-time Adaptive Intervention, to Improve HIV Prevention and Substance Use in Youth Experiencing Homelessness

The University of Texas Health Science Center, Houston — NA

TrialRECRUITING
Oct 2024Adaptation of an Intervention Addressing Barriers to PrEP Use Among Pregnant Women in Zimbabwe

Massachusetts General Hospital — NA

TrialRECRUITING
Sep 2024Women Focused Encounters for Resilience Independence Strength and Eudaimonia

University of California, San Diego — NA

TrialRECRUITING
Jul 2024Vaccine Immunity and Inflammation in the Aging Person Living With HIV

Hennepin Healthcare Research Institute — PHASE4

TrialRECRUITING
May 2024Differentiated Service Delivery (DSD) for People Living with HIV (PLHIV) and Comorbidities

Chinese University of Hong Kong — NA

TrialRECRUITING
Feb 2024PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.

Desmond Tutu HIV Foundation — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

4 available

EBANGA�

ansuvimab-zykl· Emergent Manufacturing Operations Baltimore LLCOrphan DrugAccelerated Approval

treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection

Viread

tenofovir· Gilead Sciences, Inc.■ Boxed Warning

in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older weighing at least 10 kg

Retrovir

zidovudine· Glaxo Wellcome Inc.■ Boxed Warning

Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents

Biktarvy

bictegravir, emtricitabine, and tenofovir alafenamide· Gilead Sciences, Inc.■ Boxed Warning
BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: who have no antiretrovi

BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir

Clinical Trials

3 recruitingView all trials with filters →
Phase 31 trial
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
Phase 3
Active
· Sites: Phoenix, Arizona; New Haven, Connecticut +14 more · Age: 499 yrs
Other2 trials
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
Actively Recruiting
PI: Matthew J Memoli, M.D. (National Institute of Allergy and Infectious Disea) · Sites: Bethesda, Maryland · Age: 1865 yrs
Neurodevelopmental Outcomes in ZIKV-Exposed Children
Enrolling by Invitation
PI: Sarah B Mulkey, MD, PhD (Children's National Research Institute) · Sites: Washington D.C., District of Columbia; Barranquilla, Atlántico · Age: 37 yrs

Specialists

Showing 25 of 47View all specialists →
KD
Katrin Dubischar
Specialist
PI on 1 active trial
VM
Vadim Dreyzin, MD
Specialist
PI on 1 active trial
MM
Michael McDonnell, MD
Specialist
PI on 1 active trial
JM
Jenny Low, MBBS
Specialist
PI on 3 active trials
GM
Grace L Chen, M.D.
Specialist
PI on 1 active trial
JP
Jill F. Lebov, PhD
Specialist
PI on 1 active trial
AP
Ana Maria B de Filippis, PhD
Specialist
PI on 1 active trial
GM
Guilherme A Calvet, MD,PhD
Specialist
PI on 1 active trial
MM
Marcus VG Lacerda, MD,PhD
INDIANAPOLIS, IN
Specialist
PI on 1 active trial
RP
Rafael FO França, PhD
Specialist
PI on 1 active trial
MP
Myrielle Dupont-Rouzeyrol, PhD
Specialist
PI on 4 active trials
AM
Anna Durbin, MD
BALTIMORE, MD
Specialist
PI on 31 active trials1 Zika virus disease publication
MM
Mario A Rojas, MD, MPH
Specialist
PI on 3 active trials
MM
Matthew J Memoli, M.D.
BETHESDA, MD
Specialist
PI on 6 active trials
MM
Martin R Gaudinski, M.D.
BETHESDA, MD
Specialist
PI on 2 active trials
AM
Anna Durbin, M.D.
BALTIMORE, MD
Specialist
PI on 2 active trials
AD
Axel Kroeger, Prof. Dr.
Specialist
PI on 1 active trial
LM
Luiz F Oliveira, M.D.
Specialist
PI on 1 active trial
CP
Cameron Simmons, Prof.
Specialist
PI on 1 active trial
FP
Frances Chu, PhD
LA MESA, CA
Specialist
PI on 1 active trial
RD
Rocio Cardenas, Research Dr.
Specialist
PI on 1 active trial
OF
Olivier Flechelles
Specialist
PI on 1 active trial4 Zika virus disease publications
GL
Grace LUI
Shatin, CA
Specialist

Rare Disease Specialist

PI on 5 active trials65 Zika virus disease publications
MM
Mehri McKellar, MD
Durham, North Carolina
Specialist

Rare Disease Specialist

PI on 3 active trials
LP
Louis Bujan, MD PhD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
⚗️ Trial Site

Children's Hospital of Philadelphia

📍 Philadelphia, Pennsylvania

👤 Study Director

👤 Richard Neibeger, MD

⚗️ Trial Site

Nationwide Children's Hospital

📍 Columbus, Ohio

⚗️ Trial Site

University of Pennsylvania

📍 Philadelphia, Pennsylvania

⚗️ Trial Site

University of Utah

📍 Salt Lake City, Utah

👤 Anthony A. Amato, MD

👤 Richard Neibeger, MD

⚗️ Trial Site

The University of Texas Health Science Center at Houston

📍 Houston, Texas

👤 Alia Warner, Ph.D.

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

Financial Resources

2 resources
Viread(tenofovir)Gilead Sciences, Inc.
Biktarvy(bictegravir, emtricitabine, and tenofovir alafenamide)Gilead Sciences, Inc.

Travel Grants

No travel grants are currently matched to Zika virus disease.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Zika virus diseaseForum →

No community posts yet. Be the first to share your experience with Zika virus disease.

Start the conversation →

Latest news about Zika virus disease

Disease timeline:

New recruiting trial: Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

A new clinical trial is recruiting patients for Zika virus disease

New trial: Screen Smart: Using Digital Health to Improve HIV Screening and Prevention

Phase NA trial recruiting. Universal Opt-out HIV Screening

New trial: Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV

Phase NA trial recruiting.

New trial: MAPS PrEP Van Study

Phase PHASE4 trial recruiting. Pre-Exposure Prophylaxis (PrEP)

New trial: Women Focused Encounters for Resilience Independence Strength and Eudaimonia

Phase NA trial recruiting. Acceptance and Commitment Therapy (ACT)

New trial: HIV-HEART Aging Study

Phase NA trial recruiting.

New trial: Differentiated Service Delivery (DSD) for People Living with HIV (PLHIV) and Comorbidities

Phase NA trial recruiting.

New trial: Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CA

Phase PHASE3 trial recruiting. Cabotegravir Tablets

New trial: CAR-T Cells for HIV Infection

Phase PHASE1 trial recruiting. Cyclophosphamide

New trial: A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by C

Phase PHASE1 trial recruiting. CH505M5 N197D mRNA-gp160

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How can I confirm whether I have Zika virus or a similar infection like dengue?,I am pregnant — what monitoring and testing do you recommend for my baby?,How long should I wait before trying to become pregnant after a Zika infection or exposure?,What signs of Guillain-Barré syndrome should I watch for, and when should I go to the emergency room?,Can I still transmit the virus to others, and for how long should I take precautions?,What developmental screenings and specialist referrals does my baby need if born with congenital Zika syndrome?,Are there any clinical trials for Zika vaccines or treatments that I could participate in?

Common questions about Zika virus disease

What is Zika virus disease?

Zika virus disease (also called Zika fever or simply Zika) is an infectious disease caused by the Zika virus, which is primarily spread through the bite of infected Aedes mosquitoes — the same type of mosquito that spreads dengue and chikungunya. The virus can also be transmitted from a pregnant mother to her unborn baby, through sexual contact, and through blood transfusions. Most people infected with Zika virus have mild symptoms or no symptoms at all. When symptoms do occur, they typically include fever, rash, joint pain, and red eyes (conjunctivitis), lasting several days to a week. While

How is Zika virus disease inherited?

Zika virus disease follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Zika virus disease?

Yes — 3 recruiting clinical trials are currently listed for Zika virus disease on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Zika virus disease?

25 specialists and care centers treating Zika virus disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Zika virus disease?

3 patient support programs are currently tracked on UniteRare for Zika virus disease. See the treatments and support programs sections for copay assistance, eligibility, and contact details.